MedPath

Takeda Pharmaceutical Company Ltd

🇯🇵Japan
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Phase 2
Terminated
Conditions
Diabetic Neuropathies
Interventions
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
221
Registration Number
NCT00756041

Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia

Phase 2
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
378
Registration Number
NCT00755508

Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2008-09-19
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
265
Registration Number
NCT00755846

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia

Phase 2
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
First Posted Date
2008-09-19
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
472
Registration Number
NCT00755495

Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Placebo
First Posted Date
2008-09-19
Last Posted Date
2010-06-02
Lead Sponsor
Takeda
Target Recruit Count
259
Registration Number
NCT00756002

Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus
Interventions
First Posted Date
2008-09-18
Last Posted Date
2010-07-05
Lead Sponsor
Takeda
Target Recruit Count
312
Registration Number
NCT00754403

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Phase 2
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-09-15
Last Posted Date
2012-07-27
Lead Sponsor
Takeda
Target Recruit Count
102
Registration Number
NCT00752609

Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.

Phase 2
Completed
Conditions
Anemia
Interventions
First Posted Date
2008-09-15
Last Posted Date
2012-08-15
Lead Sponsor
Takeda
Target Recruit Count
59
Registration Number
NCT00752791

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Phase 3
Completed
Conditions
Generalized Anxiety Disorder
Interventions
Drug: Placebo
First Posted Date
2008-09-01
Last Posted Date
2014-03-03
Lead Sponsor
Takeda
Target Recruit Count
301
Registration Number
NCT00744627

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2008-08-15
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
560
Registration Number
NCT00735709
© Copyright 2025. All Rights Reserved by MedPath